Aim: A study to compare the addition of Blinatumomab in combination with chemotherapy in patients diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B‑ALL and the treatment of patients with localized B-cell Lymphoblastic Lymphoma (B-LLy).
What can we help you find?